Australian institute is first to adopt Livecyte system in APAC region

The Translational Research Institute (TRI), based in Brisbane, has become the first centre in Australia and the Asia Pacific region to adopt the Livecyte Cell Imaging and Analysis system — developed by UK company Phasefocus.

Livecyte enables quantitative, label free, live cell imaging and analysis of single and multiple cell types in heterogeneous cell populations using ptychographic quantitative phase imaging (QPI). Requiring only low-level illumination, Livecyte provides a gentle experimental environment which mimics the behaviour of cells in ‘real life’ making it suitable for more clinically and physiologically relevant primary and stem cell populations, alongside traditional cell assays.

TRI was derived from a partnership between Queensland Health; Princess Alexandra Hospital, University of Queensland, Queensland University of Technology, Mater Research & its health partner DSM biologics. It was formed to enhance collaboration between science, healthcare and industry with the purpose of accelerating the application of innovative scientific research to improve healthcare outcomes.

Senior microscopy scientist Dr Sandrine Roy who manages the facility commented: “The label-free imaging potential for primary cell studies is very exciting in tracking cell behaviour with minimal interference and we are all really excited to have such a powerful automated system to help with the data analysis.”

“We are delighted by TRI’s decision to purchase Livecyte for their microscopy facility,” added Tracey Zimmermann, Phasefocus VP Global Sales. “This is a significant result for Phasefocus and we have great expectations for Livecyte in the Asia Pacific region, supported by the achievements of the researchers in Brisbane.”